
Alterations of the outer retinal layers from age-related macular degeneration (AMD) can interfere with the automated segmentation of the individual retinal layer thicknesses when using macular optical coherence tomography (OCT).

The company noted that pegcetacoplan, designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases, was granted Fast Track designation by the FDA for the treatment of geographic atrophy.

Additional information requested for BLA for ONS-5010, Outlook to resubmit by September

Alterations of the outer retinal layers from age-related macular degeneration (AMD) can interfere with the automated segmentation of the individual retinal layer thicknesses when using macular optical coherence tomography (OCT).

Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous injection option being developed for wet AMD and DME. The anti-VEGF candidate will enter a Phase 2 study later this year.

A discovery by investigators at the National Eye Institute sheds light on tissue targeted by age-related macular degeneration and other diseases.

Professor Anat Loewenstein, MD, discusses data regarding the efficacy of faricimab at targeting both the VEGF and Ang2 pathways in patients with neovascular AMD and diabetic macular edema.

As more and more practices embrace dark adaptation testing, AdaptDx technology has become a staple in primary eye care.

A discovery by investigators at the National Eye Institute sheds light on tissue targeted by age-related macular degeneration and other diseases.

The Eye Van, operated by Vision Loss Rehabilitation Canada, is a mobile medical clinic that delivers eye care in northern Ontario communities where ophthalmology services aren't readily available.

Apellis revealed 18-month data for their investigational C3 therapy pegcetacoplan, unveiling continuous lesion growth reduction in eyes with geographic atrophy with monthly and every-other-month injections.

As more and more practices embrace dark adaptation testing, AdaptDx technology has become a staple in primary eye care.

The OpRegen trial is a cell therapy trial, looking to explore potential safety and efficacy for patients with advanced dry age-related macular degeneration (AMD).

The data presented at ARVO showed single subcutaneous doses of D-4517.2 were safe, well-tolerated in healthy subjects.

According to the ALOFT study, patients demonstrate improved long-term vision in real-world setting after wet AMD conversion compared to current standard of care.

Variable TULP1 missense mutations in inherited retinal diseases.

Jennifer I. Lim, MD, FARVO, FASRS, reviews the 2-year results of the YOSEMITE and RHINE trials, outlining the efficacy, durability, and safety of faricimab in diabetic macular edema.

The study found no association between treatment and the risk of chronic kidney disease or end-stage renal disease.

The intravitreal implant (OTX-TKI) is being evaluated to treat wet age-related macular degeneration in a phase 1b clinical trial.

The axitinib intravitreal implant (OTX-TKI) is being evaluated to treat wet age-related macular degeneration in a phase 1b clinical trial.

A poll for retina specialists regarding their attendance at the 2022 Retina World Congress in Fort Lauderdale, Florida. This poll is now closed.

According to the ALOFT study, patients demonstrate improved long-term vision in real-world setting after wet AMD conversion compared to current standard of care.

Apellis Pharmaceuticals releases results of their Geographic Atrophy Insights Survey (GAINS), revealing a large emotional toll and significant decrease in independence for patients with geographic atrophy.

A poll for retina specialists regarding their attendance at the Association for Research in Vision and Ophthalmology 2022 Meeting in Denver, Colorado. This poll is now closed.

Investigators found that patients with neovascular age-related macular degeneration in all countries included in the study lost vision as a result of the lockdown and reduced number of treatments during the COVID-19 pandemic.

If the Biologics License Application is approved by the FDA, the company could receive 12 years of marketing exclusivity for an FDA-approved alternative for the most frequently used anti-VEGF treatment in wet AMD patients in the United States.

If the BLA is approved, the company could receive 12 years of marketing exclusivity for an FDA-approved alternative for the most frequently used anti-VEGF treatment in wet AMD patients in the United States.

The company is planning a Phase 2 trial with an optimized formulation in wet AMD that is expected to start in fourth quarter of 2022.